Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s shares closed yesterday at $24.31.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Flynn is a 3-star analyst with an average return of 2.5% and a 52.78% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Gilead Sciences, and Merck & Company.
In addition to Morgan Stanley, Pfizer also received a Hold from Bernstein’s Justin Smith in a report issued on June 18. However, on June 17, Guggenheim maintained a Buy rating on Pfizer (NYSE: PFE).
The company has a one-year high of $31.54 and a one-year low of $20.92. Currently, Pfizer has an average volume of 47.96M.
Read More on PFE:
- Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says
- Pfizer’s Phase 3 Study on Ibuzatrelvir: A Potential Game Changer in COVID-19 Treatment
- Pfizer’s Rimegepant Study: A Potential Game-Changer in Pediatric Migraine Prevention
- Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for Multiple Myeloma Treatment
- Pfizer’s Promising Phase 3 Study on Elranatamab in Multiple Myeloma